Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting
Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting
Capricor Therapeutics 宣佈與 FDA 就杜興氏肌肉萎縮症 CAP-1002 計劃舉行B型會議，美國食品藥品管理局的反饋支持BLA前會議的請求以及在即將舉行的第二季度Type-B FDA會議之後隨後的滾動BLA提交
Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting
Capricor Therapeutics 宣佈與 FDA 就杜興氏肌肉萎縮症 CAP-1002 計劃舉行B型會議，美國食品藥品管理局的反饋支持BLA前會議的請求以及在即將舉行的第二季度Type-B FDA會議之後隨後的滾動BLA提交
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。